MD

Pediatrix Medical Group

Stock NYSE – Stock Market Prices, News & Analysis

Pediatrix Medical Group Inc is a healthcare provider specializing in pediatric and obstetric services in the United States.

$ 21.39
0.99 %

Pediatrix Medical Group

$ 21.39
0.99 %
MD

Pediatrix Medical Group Inc is a healthcare provider specializing in pediatric and obstetric services in the United States.

Price history of Pediatrix Medical Group
Price history of Pediatrix Medical Group

Performance & Momentum

6 Months 24.24 %
1 Year 45.55 %
3 Years 41.65 %
5 Years 16.69 %

Strategic Analysis

Pediatrix Medical Group • 2026

Pediatrix Medical Group Inc positions itself as a specialized player in pediatric and obstetric care in the United States, offering essential services in a healthcare segment with high barriers to entry. Its model relies on targeted expertise and a deep presence in a niche medical field with recurring demand.

Strengths
  • Clear specialization in the pediatric and obstetric sectors, reducing direct competition
  • Established position in a U.S. market with a constant need for specialized healthcare services
  • Current model tied to the essential nature of medical care for mothers and children
Weaknesses
  • Sensitivity to complex regulatory changes in the U.S. healthcare sector
  • Recent mixed long-term performance, which may reflect structural or competitive challenges
Momentum

Recent momentum is strong, with notable improvement over the last few semesters, reflecting a renewed interest from investors potentially linked to improved operational execution or revised outlooks. This dynamism encourages a positive approach while remaining vigilant of regulatory uncertainties.

Analysis performed 1 month ago

Was this page helpful?

Your feedback helps us improve our research.

Take control
of your investments

Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.

  • Real-time multi-portfolio tracking
  • AI analysis of your positions
  • Counter your cognitive biases
Anantys Invest on iPhone